Back to top
more

AstraZeneca (AZN)

(Real Time Quote from BATS)

$80.48 USD

80.48
2,626,827

-0.68 (-0.84%)

Updated Sep 11, 2024 03:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 12% (30 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AstraZeneca's Imfinzi Fails in Lung Cancer Study, Stock Down

by Zacks Equity Research

AstraZeneca (AZN) announced that Imfinzi as a monotherapy or in combination with tremelimumab failed to improve overall survival in first-line NSCLC. The combination had also failed to improve progression free survival last year.

Mark Vickery headshot

Top Analyst Reports for Union Pacific, UPS & American Tower

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Union Pacific (UNP), United Parcel Service (UPS) and American Tower (AMT).

Pharma Stock Roundup: FDA Updates on MRK, AZN's Cancer Drugs, Bayer's Q3 Earnings

by Zacks Equity Research

FDA provides updates on Merck (MRK), AstraZeneca (AZN) and Roche (RHHBY) for their cancer drugs. Bayer (BAYRY) reports strong third-quarter results.

AstraZeneca to Sell US Rights of Lung Infection Drug to Sobi

by Zacks Equity Research

AstraZeneca (AZN) to sell U.S. rights of Synagis to Sobi for an upfront consideration of $1.5 billion as it streamlines its portfolio

Tesaro, Clovis Rally on FDA Priority Review for Lynparza sNDA

by Zacks Equity Research

PARP inhibitor makers get a boost following priority review for AstraZeneca???s (AZN) label expansion application for Lynparza as a first-line maintenance treatment for ovarian cancer.

AstraZeneca's Lynparza Gets Priority Review in 1st Line Use

by Zacks Equity Research

AstraZeneca (AZN) and partner Merck's sNDA looking for label expansion of Lynparza in the first-line setting gets FDA's priority review.

Inovio (INO) Q3 Loss Narrower Than Expected, Revenues Meet

by Zacks Equity Research

Inovio Pharmaceuticals' (INO) Q3 loss betters estimates. Also, revenues match the consensus mark.

Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q3

by Zacks Equity Research

Merrimack (MACK) discourages with Q3 loss, falling shy of estimates as well as deteriorates from the year-ago quarter's figure. Also, the company fails to reap any revenues in the period.

Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug

by Zacks Equity Research

Lilly (LLY) and AstraZeneca (AZN) report third-quarter results. Pfizer (PFE) gains FDA approval for a new cancer medicine.

AstraZeneca's (AZN) Q3 Earnings Beat, New Drugs Drive Sales

by Zacks Equity Research

AstraZeneca (AZN) beats earnings and sales estimates in the third quarter and maintains previously issued outlook for 2018. AstraZeneca's newer medicines sales rise 86% in the quarter.

Ironwood (IRWD) Q3 Earnings & Revenues Miss, Shares Down

by Zacks Equity Research

Ironwood Pharmaceuticals (IRWD) misses estimates for both earnings and sales in the third quarter. The company maintains its guidance for operating expenses.

BMY vs. AZN: Which Stock Is the Better Value Option?

by Zacks Equity Research

BMY vs. AZN: Which Stock Is the Better Value Option?

Pharma Stock Roundup: MRK, BMY Q3 Earnings, Cancer Data Presentations at ESMO

by Zacks Equity Research

Merck (MRK) and Bristol-Myers (BMY) report mixed third-quarter results. Pharma bigwigs present cancer data at ESMO.

Merck (MRK) Beats on Q3 Earnings, Lags Sales, Ups EPS View

by Zacks Equity Research

Merck (MRK) beat estimates for earnings while missing the same for sales in third-quarter 2018. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand trends.

Agios Rides on Tibsovo Approval Amid Reliance on Celgene

by Zacks Equity Research

Agios (AGIO) aims at commercializing its newly approved leukemia drug Tibsovo, which has great potential in the AML market. Heavy reliance on Celgene for royalties and collaboration revenues is a woe.

QIAGEN Launches QIAstat-Dx Panel in Europe, Widens Suite

by Zacks Equity Research

QIAGEN (QGEN) continues to expand test menu; latest European launch to boost portfolio and top line.

    Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs

    by Zacks Equity Research

    Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well.

      The Zacks Analyst Blog Highlights: AstraZeneca, salesforce, Mastercard, Lam Research and Koninklijke

      by Zacks Equity Research

      The Zacks Analyst Blog Highlights: AstraZeneca, salesforce, Mastercard, Lam Research and Koninklijke

      Merck's Keytruda on a Roll in a Thriving Anti-PD-L1 Market

      by Zacks Equity Research

      Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.

      Mark Vickery headshot

      Top Analyst Reports for AstraZeneca, Salesforce & Mastercard

      by Mark Vickery

      Today's Research Daily features new research reports on 12 major stocks, including AstraZeneca (AZN), salesforce.com (CRM) and Mastercard (MA)

      AstraZeneca's (AZN) Lynparza Gets Another Orphan Drug Status

      by Zacks Equity Research

      AstraZeneca (AZN) and partner Merck's Lynparza receive Orphan Drug designation (ODD) by the FDA for the treatment of pancreatic cancer.

        3 Large-Cap Pharma Stocks Performing Better Than Industry

        by Zacks Equity Research

        We focus on three large-cap pharma stocks that are outperforming the industry on the back of their diverse portfolio.

        J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion

        by Zacks Equity Research

        Johnson & Johnson's (JNJ) Xarelto gets FDA approval for reducing risk of major cardiovascular events in chronic coronary or peripheral artery disease patients.

        Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts

        by Zacks Equity Research

        Merrimack (MACK) focuses on the development of its two early-stage pipeline candidates, MM-121 and MM-310. The candidates have been progressing well and are imperative to the company's growth.

        Sweta Killa headshot

        Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

        by Sweta Killa

        Sector ETF report for PPH